Table 3.
Adverse drug reactions and the medication for ADRs in the study groups
| All (n = 94) | Discontinued group (n = 41) | Continued group (n = 53) | p-value | |
|---|---|---|---|---|
| Any ADRs | 71 (75.5) | 34 (82.9) | 37 (69.8) | 0.0132 |
| ADRs leading to: | ||||
| Death | 5 (5.3) | 5 (12.2) | 0 | < 0.0001 |
| Lost follow-up | 8 (8.5) | 4 (9.8) | 4 (7.6) | 0.6715 |
| Dose reduction | 14 (14.9) | 5 (12.2) | 9 (17.0) | 0.6864 |
| Discontinuation | 24 (25.5) | 17 (41.5) | 7 (13.2) | < 0.0001 |
| Temporary | 22 (23.4) | 15 (36.6) | 7 (13.2) | < 0.0001 |
| Permanent | 2 (2.1) | 2 (4.9) | 0 (0) | 0.0453 |
| Medication for ADRs: | ||||
| For nausea/vomiting | 53 (56.4) | 17 (41.5) | 36 (67.9) | 0.0103 |
| For diarrhea | 45 (47.9) | 12 (29.3) | 33 (62.3) | 0.0015 |
| For hepatic dysfunction | 21 (22.3) | 8 (19.5) | 13 (24.5) | 0.5626 |
Values are displayed as number (%)
ADR adverse drug reactions